Malak Ghaddar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Malak Ghaddar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Adel El-Kaakour
Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
1 shared publication- Bingyue Zhu
British Columbia Renal Agency, Vancouver, British Columbia, Canada
1 shared publication - Dilshani Induruwage
British Columbia Renal Agency, Vancouver, British Columbia, Canada
1 shared publication - Erica Daina
Clinical Research Center for Rare Diseases “Aldo e Cele Daccò”, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
1 shared publication - Fernando Caravaca-Fontán
Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre , Madrid
1 shared publication - Gema Fernández-Juárez
Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
1 shared publication
Latest Publications
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1119-1131
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
Key Points: Lower eGFR, paraprotein presence, and interstitial fibrosis were associated with a higher risk of kidney outcome. Native disease (versus recurrence post-transplantation), White ethnicity, and lower C4 levels were associated with a lower risk of kidney outcome. A 50% reduction in proteinuria from baseline to a value 2 D: 53%, C-statistic: 0.84 [95% confidence interval, 0.82 to 0.86], integrated calibration index: 0.31) and maintained robustness after internal validation. A 50% reduction in proteinuria from baseline to a value <1 g/d was associated with a lower risk of outcome independent of other risk factors (hazard ratio, 0.35; 95% confidence interval, 0.12 to 0.97). Conclusions: Our study evaluated the baseline clinical and histologic parameters associated with kidney outcomes using the largest C3G/idiopathic IC-MPGN cohort to date. These factors were included in a prediction model to assess individual patient risk. Our results provide an evidence-based definition of proteinuria remission that can be used for patient care and in clinical trials. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_08_27_CJASNAugust.20.8.82.mp3
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1119-1131
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
Key Points: Lower eGFR, paraprotein presence, and interstitial fibrosis were associated with a higher risk of kidney outcome. Native disease (versus recurrence post-transplantation), White ethnicity, and lower C4 levels were associated with a lower risk of kidney outcome. A 50% reduction in proteinuria from baseline to a value 2 D: 53%, C-statistic: 0.84 [95% confidence interval, 0.82 to 0.86], integrated calibration index: 0.31) and maintained robustness after internal validation. A 50% reduction in proteinuria from baseline to a value <1 g/d was associated with a lower risk of outcome independent of other risk factors (hazard ratio, 0.35; 95% confidence interval, 0.12 to 0.97). Conclusions: Our study evaluated the baseline clinical and histologic parameters associated with kidney outcomes using the largest C3G/idiopathic IC-MPGN cohort to date. These factors were included in a prediction model to assess individual patient risk. Our results provide an evidence-based definition of proteinuria remission that can be used for patient care and in clinical trials. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_08_27_CJASNAugust.20.8.82.mp3
- Open Access
- 23 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (2) , 219-226
Risk of Postoperative Hypermagnesemia in Cardiopulmonary Bypass–Assisted Cardiovascular Surgery
Key Points: The incidence of hypermagnesemia after cardiovascular surgeries using cardiopulmonary bypass is 53.2%. Most patients had mild hypermagnesemia. Cardioplegic solutions with higher magnesium content and lower eGFR were independently linked to an increased risk of hypermagnesemia. Large multicenter studies should explore the effects of hypermagnesemia on clinical outcomes in patients with advanced CKD undergoing cardiopulmonary bypass surgeries. Background: Magnesium (Mg) administration is a common practice in cardiovascular surgeries using cardiopulmonary bypass (CPB). However, concerns persist regarding the risk of hypermagnesemia, particularly in patients with kidney dysfunction. The aims of this study were to determine the incidence of postoperative hypermagnesemia in CPB-assisted cardiovascular surgeries and identify the associated risk factors. Methods: This was a retrospective cohort study conducted at a tertiary medical center. Data from adult patients undergoing open-heart surgery using CPB between 2018 and 2020 were analyzed. Sociodemographic, perioperative, and clinical variables were collected from electronic medical records. Logistic regression was used to identify independent risk factors of hypermagnesemia. Results: Of the 278 patients analyzed, 53.2% developed postoperative hypermagnesemia (Mg ≥2.5 mg/dl). Mild hypermagnesemia (Mg, 2.5–3.9 mg/dl) was most common with no significant effect on clinical outcomes observed. Patients with hypermagnesemia were older, with higher comorbidity burdens and lower baseline eGFR. Cardioplegic solutions with higher Mg content and lower baseline eGFR were independently associated with hypermagnesemia (odds ratio [OR], 64.3; 95% confidence interval [CI], 12.9 to 501.1 and OR, 1.3; 95% CI, 1.1 to 1.5, respectively). Notably, ultrafiltration on CPB was associated with low risk of hypermagnesemia (OR, 0.4; 95% CI, 0.1 to 1.0; P value, 0.048). Conclusions: This study highlights the importance of mindful Mg supplementation strategies in those with advanced kidney disease. Future large-scale prospective multicenter studies should validate these findings and explore the extended effects of hypermagnesemia on clinical outcomes in patients with advanced CKD undergoing CPB surgeries.
- 23 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (2) , 219-226
Open AccessRisk of Postoperative Hypermagnesemia in Cardiopulmonary Bypass–Assisted Cardiovascular Surgery
Key Points: The incidence of hypermagnesemia after cardiovascular surgeries using cardiopulmonary bypass is 53.2%. Most patients had mild hypermagnesemia. Cardioplegic solutions with higher magnesium content and lower eGFR were independently linked to an increased risk of hypermagnesemia. Large multicenter studies should explore the effects of hypermagnesemia on clinical outcomes in patients with advanced CKD undergoing cardiopulmonary bypass surgeries. Background: Magnesium (Mg) administration is a common practice in cardiovascular surgeries using cardiopulmonary bypass (CPB). However, concerns persist regarding the risk of hypermagnesemia, particularly in patients with kidney dysfunction. The aims of this study were to determine the incidence of postoperative hypermagnesemia in CPB-assisted cardiovascular surgeries and identify the associated risk factors. Methods: This was a retrospective cohort study conducted at a tertiary medical center. Data from adult patients undergoing open-heart surgery using CPB between 2018 and 2020 were analyzed. Sociodemographic, perioperative, and clinical variables were collected from electronic medical records. Logistic regression was used to identify independent risk factors of hypermagnesemia. Results: Of the 278 patients analyzed, 53.2% developed postoperative hypermagnesemia (Mg ≥2.5 mg/dl). Mild hypermagnesemia (Mg, 2.5–3.9 mg/dl) was most common with no significant effect on clinical outcomes observed. Patients with hypermagnesemia were older, with higher comorbidity burdens and lower baseline eGFR. Cardioplegic solutions with higher Mg content and lower baseline eGFR were independently associated with hypermagnesemia (odds ratio [OR], 64.3; 95% confidence interval [CI], 12.9 to 501.1 and OR, 1.3; 95% CI, 1.1 to 1.5, respectively). Notably, ultrafiltration on CPB was associated with low risk of hypermagnesemia (OR, 0.4; 95% CI, 0.1 to 1.0; P value, 0.048). Conclusions: This study highlights the importance of mindful Mg supplementation strategies in those with advanced kidney disease. Future large-scale prospective multicenter studies should validate these findings and explore the extended effects of hypermagnesemia on clinical outcomes in patients with advanced CKD undergoing CPB surgeries.